Knight Cardiovascular Institute, Oregon Health & Science University, Portland, Oregon.
Divisions of Infectious Diseases and Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, Minnesota.
JACC Clin Electrophysiol. 2017 Oct;3(10):1158-1167. doi: 10.1016/j.jacep.2017.02.016. Epub 2017 May 31.
This study sought to determine whether the nonabsorbable TYRX Antibacterial Envelope (TYRX) reduces major cardiovascular implantable electronic device (CIED) infections 12 months after implant.
TYRX is a monofilament polypropylene mesh impregnated with minocycline and rifampin specifically designed to hold a CIED in place and elute antimicrobials over time. There are limited data on its ability to reduce CIED infections.
We prospectively enrolled patients who underwent generator replacement with an implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy device (CRT), treated with TYRX. The primary endpoints were major CIED infection and CIED mechanical complications. Given the differences in infection rates among ICD and CRT patients, 3 different control populations were used: a published benchmark rate for ICD patients, and both site-matched and comorbidity-matched controls groups for CRT patients.
Overall, a major CIED infection occurred in 5 of 1,129 patients treated with TYRX (0.4%; 95% confidence interval: 0.0% to 0.9%), significantly lower than the 12-month benchmark rate of 2.2% (p = 0.0023). Among the TYRX-treated CRT cohort, the major CIED infection rate was 0.7% compared with an infection rate of 1.0% and 1.3% (p = 0.38 and p = 0.02) in site-matched and comorbidity-matched control groups, respectively. Among the ICD group, the 12-month infection rate was 0.2% compared with the published benchmark of 2.2% (p = 0.0052). The most common CIED mechanical complication in study patients was pocket hematoma, which occurred in 18 of the 1,129 patients (1.6%; 95% confidence interval: 0.8 to 2.5), which is comparable with a published rate of 1.6%.
Use of TYRX was associated with a lower major CIED infection rate. (TYRX™ Envelope for Prevention of Infection Following Replacement With a CRT or ICD; [Centurion]; NCT01043861/NCT01043705).
本研究旨在确定不可吸收 TYRX 抗菌封套(TYRX)是否能降低植入后 12 个月主要心血管植入式电子设备(CIED)感染的风险。
TYRX 是一种单丝聚丙烯网,涂有米诺环素和利福平,专门设计用于固定 CIED 并随时间释放抗生素。关于其降低 CIED 感染能力的资料有限。
我们前瞻性地招募了接受植入式心律转复除颤器(ICD)或心脏再同步治疗装置(CRT)更换的患者,并用 TYRX 进行治疗。主要终点是主要 CIED 感染和 CIED 机械并发症。鉴于 ICD 和 CRT 患者的感染率存在差异,我们使用了 3 种不同的对照人群:ICD 患者的已发表基准率,以及 CRT 患者的站点匹配和合并症匹配对照组。
总体而言,在 1129 例接受 TYRX 治疗的患者中,有 5 例(0.4%;95%置信区间:0.0%至 0.9%)发生了主要 CIED 感染,明显低于 12 个月的 2.2%基准率(p=0.0023)。在接受 TYRX 治疗的 CRT 队列中,主要 CIED 感染率为 0.7%,而在站点匹配和合并症匹配对照组中,感染率分别为 1.0%和 1.3%(p=0.38 和 p=0.02)。在 ICD 组中,12 个月的感染率为 0.2%,而与已发表的基准率 2.2%相比(p=0.0052)。研究患者中最常见的 CIED 机械并发症是口袋血肿,在 1129 例患者中有 18 例(1.6%;95%置信区间:0.8%至 2.5%),与已发表的 1.6%的比率相当。
使用 TYRX 与较低的主要 CIED 感染率相关。(TYRX™ 封套用于预防 CRT 或 ICD 更换后的感染;[Centurion];NCT01043861/NCT01043705)。